Yttrium-90 Radiolabeled Daclizumab, an Anti-CD25 Monoclonal Antibody Provides Effective Therapy for Refractory and Relapsed Hodgkin’s Lymphoma

Wednesday, October 10, 2012 — Poster Session II
Noon – 2:00 p.m	Natcher Conference Center, Building 45	NCI	CLIN/TRANS-23

Authors

• T.A. Waldmann
• J.E Janik
• J.C. Morris
• D. O'Mahony
• S. Pittaluga
• E.S. Jaffe
• M.W. Brechbiel
• C.H. Paik
• M. Whatley
• J.D. White
• D.M Stewart
• S. Fioravanti
• C.C. Lee
• C.K. Goldman
• B.R. Bryant
• J.A. Carrasquillo

Abstract

Refractory or relapsed Hodgkin’s lymphoma (HL) patients were treated with up to seven intravenous infusions of the anti-CD25 antibody 90Y-daclizumab. The study’s scientific basis is that most normal cells do not express CD25 whereas it is expressed by some Reed-Sternberg cells and by rosetting polyclonal T cells in lymphomatous masses. Yttrium-90 provides strong beta emissions that kill tumor cells at a distance by crossfire. In 30 HL patients treated with 90Y-daclizumab there were 6 with progressive disease, 5 stable disease, 7 partial responses and 12 with complete responses. Responses were seen in patients whose Reed-Sternberg cells expressed CD25 and in those whose neoplastic cells were CD25 negative provided that associated rosetting T cells expressed CD25. Toxicities were limited to myelodysplastic syndrome in three cases and transient bone-marrow suppression. In conclusion, repeated 90Y-daclizumab infusions predominantly directed toward non-malignant T cells rosetting around Reed-Sternberg cells provided effective therapy for select HL patients.

back to top